Biosensors

Biosensors: stock is -4.8% at $1.50 on above avg volume.
Biosensors’ price action coincides with news that “the first fully biodegradable coronary artery stent implanted in humans proved safe in a 10yr study” published in Circulation, an American Heart Association journal.

Stents are mesh tubes inserted into coronary arteries to help prop them open and allow for blood flow to the heart muscle.
The biodegradable Igaki-Tamai stent is used in 9 EU countries and Turkey -- but not in the US -- to treat peripheral artery disease (PAD), the disorder which results from fatty deposits that narrow leg arteries.

While no countries have approved the Igaki-Tamai stent for treating clogged heart arteries (and such approval may take time), this signals that biodegradable stents as a new competing technology could be closer to hand than expected. Current treatment options comprising bare-metal stents and drug-eluting stents (DES), and Biosensors’ main pdt, BioMatrix is one such DES approved for use outside the US.